All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy

Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).